Krystal Biotech (KRYS) Income from Continuing Operations (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Income from Continuing Operations of 54768000.0 for Q2 2026, up 42.87% year-over-year from 38333000.0 in Q2 2025, and down 2.08% on a QoQ basis from 55932000.0 in Q1 2026.
Powered by 
Analysis
Krystal Biotech (KRYS) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Income from Continuing Operations for 11 years, with the latest figure at 54768000.0 in Q2 2026.
- Income from Continuing Operations for Q2 2026 came in at 54768000.0, up 42.87% year-over-year; the trailing twelve-month figure through Jun 2026 was 241458000.0 (up 64.58% YoY), and the FY2025 annual result was 204831000.0, up 129.74% from the prior year.
- Income from Continuing Operations fell to 54768000.0 in Q2 2026, from 55932000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 80747000.0 in Q3 2023 and troughed at 114315000.0 in Q1 2023.
- A 5-year average of 5828000.0 and a median of 21368500.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2022, when Income from Continuing Operations tumbled 106.66%; it then soared 3730.15% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 34024000.0 in 2022, then soared by 125.55% to 8692000.0 in 2023, then soared by 423.62% to 45513000.0 in 2024, then rose by 12.91% to 51391000.0 in 2025, then grew by 6.57% to 54768000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 54768000.0 in Q2 2026, 55932000.0 in Q1 2026, and 51391000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Krystal Biotech | 10.61 Bn | 9.76 Bn | 112.79 Mn | 54.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.77 Mn |
| Mar 31, 2026 | 55.93 Mn |
| Dec 31, 2025 | 51.39 Mn |
| Sep 30, 2025 | 79.37 Mn |
| Jun 30, 2025 | 38.33 Mn |
| Mar 31, 2025 | 35.70 Mn |
| Dec 31, 2024 | 45.51 Mn |
| Sep 30, 2024 | 27.17 Mn |
| Jun 30, 2024 | 15.57 Mn |
| Mar 31, 2024 | 932,000.00 |
| Dec 31, 2023 | 8.69 Mn |
| Sep 30, 2023 | 80.75 Mn |
| Jun 30, 2023 | -33.21 Mn |
| Mar 31, 2023 | -48.25 Mn |
| Dec 31, 2022 | -28.24 Mn |
| Sep 30, 2022 | -31.38 Mn |
| Jun 30, 2022 | -29.10 Mn |
| Mar 31, 2022 | -51.26 Mn |
| Dec 31, 2021 | -22.03 Mn |
| Sep 30, 2021 | -15.65 Mn |